1Wohrle J, Grebe OC, N usser T, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial Infarction or unstable angina undergoing coronary angioplasty. Circulation, 2003,107 : 1840.
2Galache Osuna JG, Sanchez-Rubio J, Calvo I,et al. Does intracoronary abciximab improve the outcome of percutaneous coronary Interventions? A randomized controlled trial. Rev Esp Cardiol,2006,59:567.
3Gibson CM, Jennings LK, Murphy SA, et al. Association between platelet receptor occupancy after eptifibatide (Integrilin) therapy and patency, myocardial perfusion, and ST segment resolution among patients with ST-segment-elevation myocardial infarction:an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. Circulation, 2004,110:679.
4Hassan W, Al-Sergani H, Al Buraiki J, et al. Immediate and intermediate results of intracoronary stand-alone bolus administration of eptifibatide during coronary intervention (ICE) study Am Heart J,2007,154:345.
7Claeys MJ, Bosmans J, Ceuninck MD,et al. Effect of Intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am J Cardiol, 2004,94 : 9
8Stoel MG, Marques KM, de Cock CC,et al. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: A randomized placebo-controlled pilot study. Catheter Cardiovasc Interv,2008,71:283.
9Lim SY, Bae EH, Jeong MH, et al. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention. Circ J,2004, 68 : 928.
10Barcin C, Denktas AE, Lennon RJ,et al. Comparison of combination therapy of adenosine and nitroprusside with adenosine a lone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interve, 2004,61 : 484.
二级参考文献29
1The RESTPRE Investigators. Effects of platelet glycoprotein IIb/IIIa blockage with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation, 1997,96: 1445.
2Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med, 1998,338:1498.
3The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med, 1998,338:1488.
4James C. Bleeding complications of glycoprotein IIb/IIIa receptor inhibitors. Am Heart J, 1999,138:S287.
5Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat unstable angina. N Engl J Med, 1988,319:1105.
6The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet, 1990,336:827.
7Jarvis B,Simpson K. Clopidogrel:a review of its use in the prevention of atherothrombosis. Drugs, 2000 ;60: 347.
8Brener SJ, Barr LA, Burehenal JE, et al. Randomized, placebocontrolled trial of platelet glycoprotein Ⅱb/Ⅲa blockade with primary PTCA Organization and Randomized Trial (RAPPORT). Circulation, 1998, 98 (8) : 734-741.
9Montalescot G, Barragan P, Wittenberg O, et al. For the ADMIRAL Investigators. Platelet glycoprotein Ⅱb/Ⅲa inhibition with coronary stenting for acute myocardial infarction. N Eng J Med, 2001, 344 ( 25 ) : 1895-1903.
10Stone GW, Grines CL, Cox DA, et al. Comparision of angioplasty with stenting, with or without abciximab, in acuete myocardial infarction. N Eng J Med, 2002, 346(13): 957-966.
